

References

L-102

1. 42 CFR 8.12 - Federal opioid treatment standards. 2017.
2. Snyder ML, Fantz CR, Melanson S. Immunoassay-based drug tests are inadequately sensitive for medication compliance monitoring in patients treated for chronic pain. *Pain Physician*. 2017;20(2S):SE1-SE9.
3. Jarvis M, Williams J, Hurford M, et al. Appropriate use of drug testing in clinical addiction medicine. *J Addict Med*. 2017;11(3):163-173.
4. American Society of Addiction Medicine (ASAM). Consensus statement: Appropriate use of drug testing in clinical addiction medicine. 2017.
5. Hayes, Inc. Hayes Medical Technology Directory Report. Pharmacogenetic and Pharmacogenomic Testing to Improve Outcomes Related to Opioid Use Disorder. Lansdale, PA: Hayes, Inc; 01/27/2022.
6. Socias ME, Ahamad K, Le Foll B, et al. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale. *Contemp Clin Trials*. 2018;69:21-27.
7. InterQual ® Level of Care Criteria 2021. Acute Care Adult. McKesson Health Solutions, LLC.